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Abstract
Background: The aim of this study was to evaluate the leptin levels in the serum and peritoneal fluid (PF) and the
protein expression in three different peritoneal ectopic implants in patients who underwent surgery for deep
infiltrating endometriosis.
Methods: All patients had been treated at the Department of Gynecology of the Pedro Ernesto University Hospital,
Rio de Janeiro. The study group consisted of 15 patients who underwent surgery for adnexal masses and infertility,
while the control group consisted of ten women who underwent surgery for tubal ligation. Peritoneal fluid and
samples tissues were collected during surgery. Serum samples were obtained before anesthesia. In this study, the
leptin levels in the serum and peritoneal fluid (PF) were evaluated by ELISA. The protein expression of leptin and its
receptors (ObR) and aromatase enzyme were evaluated by Western blot analysis of the intestine, uterosacral
ligament and vaginal septum in the ectopic implants. The t-test and one-way ANOVA with Holm-Sìdak post-test
were used, and p < 0.05 was considered to be statistically significant.
Results: Compared to the controls, the serum leptin levels (control = 14.7 ng/mL ± 2.63, endometriosis = 19.2 ng/mL ±
1.84, p < 0.0001) were increased, while in PF, there was no difference (control = 6.68 ng/mL ± 0.43, endometriosis = 7.71
ng/mL ± 0.59, p = 0.18). Comparing women with and without ovarian implants, the leptin levels in both the serum and
PF were significantly higher in women without ovarian implants (serum: with ovarian implant = 15.85 ± 1.99; without
ovarian implant = 23.14 ± 2.60; ng/mL, p = 0.04; PF: with ovarian implant = 4.28 ± 1.30; without ovarian implant = 11.18 ±
2.98;ng/mL, p = 0.048). The leptin, ObR and aromatase protein expression levels were increased in lesions in the vaginal
septum and were decreased in the intestine lesions.
Conclusion: This study reports several interesting associations between the leptin levels in serum, peritoneal fluid, and
tissue samples and the localization of the ectopic endometrium. Although this study does not provide a clear picture of
the role of leptin in the development and progression of peritoneal implants, it contributed new data that might be
useful to elucidating the enigma that is the role of leptin in endometriosis disease.
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Background
Endometriosis is a chronic, estrogen-dependent inflamma-
tory disease characterized by implantation and growth of
tissue outside of the uterus in lesions of varying sizes and
appearance containing endometrial glands and stroma as-
sociated, or not, with infertility, dysmenorrhea, and pelvic
pain [1–3]. This disease represents a public health issue
affecting 10–15 % of women of reproductive age [4]. Stud-
ies have demonstrated that endometriosis is associated
with the increased secretion of pro-inflammatory cyto-
kines and growth as well as angiogenic factors [5].
Leptin, the 16 kDa product of the Obese (Ob) gene, is
predominantly produced in adipose tissue [6]. This hor-
mone is known for its role in food intake, basal metabolism,
and reproductive function [7]. Leptin is now recognized to
have immune-regulatory, pro-inflammatory, and neoangio-
genesis functions, and it is thought to have a role in the
pathogenesis of endometriosis [5, 8–12].
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Studies evaluating the serum and peritoneal fluid (PF)
levels of leptin in patients with endometriosis have reported
conflicting results. Both high [5, 13–18] or unchanged
levels [15, 19–22] have been reported. Moreover, the possi-
bility of an association between the PF leptin levels and se-
verity of endometriosis is also controversial; some studies
have suggested a negative correlation [5, 14, 16], while
others have shown a positive correlation with more severe
forms of peritoneal endometriosis [11, 13, 15, 22].
Interestingly, only a few studies thus far have evaluated
the leptin receptor gene and/or protein expression in the
endometrial tissue of women with endometriosis [12, 23,
24], but none have evaluated the leptin expression in ec-
topic lesions.
Another interesting finding about leptin and endomet-
riosis is that patients with peritoneal implants have
higher PF leptin concentrations than women in whom
no implant was observed, suggesting that leptin may
play a role in the development of peritoneal endometri-
osis and that different biochemical phenomena might be
involved in the pathogenesis of the ovarian form of the
disease [14].
In view of the potential role of leptin in peritoneal
endometriosis, we evaluated the leptin levels in the
serum and peritoneal fluid and the protein expression in
three different peritoneal ectopic implants in patients
who underwent surgery for severe endometriosis.
Materials and methods
Patient enrollment
The study group consisted of patients who underwent
laparotomy or laparoscopy for adnexal masses and infer-
tility. The inclusion criteria for this group were stage IV
endometriosis, at least one year of primary infertility,
pain, and regular cycles before starting hormonal treat-
ment. Several peritoneal endometriotic implants were
observed in all 15 patients included in this group, and
an ovarian implant was also found in eight of the pa-
tients. The control group consisted of ten women with
proven fertility from the family-planning program of the
same hospital who were undergoing mini-laparotomy or
laparoscopy for tubal ligation and who lacked surgical
evidence of endometriosis or any ovarian pathology. All
patients in the control group had a normal pelvic cavity.
The surgeries were performed between February 8, 2013
and July 31, 2013, at the Department of Gynecology of the
Pedro Ernesto University Hospital, Rio de Janeiro.
All patients were of reproductive age and were receiving
hormonal therapy for the clinical treatment of pain associ-
ated with endometriosis or for contraception (control
group). All enrolled patients had a body mass index (BMI)
of 20.4 to 25.4 kg/m2.
The exclusion criteria were clinical and/or echographic
indications of diabetes, polycystic ovarian disease and
surgical evidence of any other genital pathology.
This study was approved by the local ethics committee
(C.E.P.: 195.160, Pedro Ernesto University Hospital, Rio
de Janeiro, Brazil). Before the procedures, all patients
signed informed consent.
Tissue specimens
Serum samples were obtained from all patients before
anesthesia. The PF samples were aspirated from the
Douglas pouch at the beginning of surgery; however,
some patients had a very low level of fluid, which made
the aspiration method impossible. In case of hemorrhage
after the insertion of trocars, the samples were not col-
lected to avoid blood contamination. As a result, only 9
patients from the peritoneal endometriosis group and 8
patients from the control group had their PF samples
analyzed. The same surgeon who performed cystectomy
removed the ovarian endometrioma. Peritoneal biopsies
of endometriosis were confirmed by histology in all pa-
tients with suspected implants at laparoscopy and were
classified according to the classification of the American
Society of Reproductive Medicine [25].
Western blotting
Approximately 500 mg of tissue was homogenized in 500
μL of lysis buffer containing 1% NP-40 (Amresco, Ohio,
USA) and a protease-inhibitor mix (Sigma-Aldrich, USA);
then, the tissue was centrifuged at 9,700 rpm at 4 °C. The
protein concentration was measured by fluorometry (Qubit
2.0, Life Technologies Corporation, CA, USA), and 20 μg
aliquots were applied to 8% SDS-polyacrylamide gel and
submitted to vertical electrophoresis; they were then trans-
ferred to nitrocellulose membranes in a semi-dry transfer
apparatus. The membranes were subsequently incubated
with antibodies (Santa Cruz, CA, USA) to leptin (1:500),
ObR (1:200) and aromatase (1:250). The expression of the
proteins under study was normalized against the expres-
sion of β-actin. The bands were visualized by chemilumin-
escence (ECL, Amersham Biosciences, Piscataway, NJ,
USA) and documented on the ChemiDoc MP System, Bio-
Rad (Life Science Research, USA). All bands were quanti-
fied using Image J software 1.42q, USA.
Leptin and estradiol levels
The concentration (ng/mL) of leptin in the serum and PF
was determined by ELISA (Millipore Corporation Billerica,
MA, USA). The concentrations (pg/mL) of estradiol in
the serum and peritoneal fluid were measured using
chemiluminescence (Kit Cobas, Roche Diagnostics,
USA) at the hormone laboratory of the Pedro Ernesto
University Hospital, Rio de Janeiro. The sensitivities of
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the assays were 0.195 ng/mL for leptin and 5.00 pg/mL
for estradiol.
Statistical analyses
Pearson’s correlation coefficient was used to evaluate the
relationship between the leptin levels and PF estradiol
levels, aromatase expression and estradiol levels. The t-
test was used to evaluate the differences between two
groups. One-way ANOVA with the Holm-Sìdak post-test
was used when 3 groups were compared. All results are
reported as the mean ± standard error of the mean (SEM),
and p-values < 0.05 were considered to be statistically sig-
nificant. The calculations were performed with GraphPad
Prism (version 6.0, GraphPad Software, CA, USA).
Results
Age, BMI and ectopic implant number
The age, BMI and ectopic implant number for each sub-
ject are shown at Table 1. All patients were classified as
having stage IV endometriosis. One inclusion criterion
was the use of hormone therapy; 87 % of patients in the
study group and 60 % of patients in the control group
were using a combined oral contraceptive (progesterone
and estrogen), and the remaining patients in both groups
were using isolated progestin therapy.
Hormone levels
Considering all fifteen patients, the peritoneal endo-
metriosis group presented with significantly high serum
leptin levels compared to the control group (control =
14.7 ± 2.63, endometriosis = 19.25 ± 1.84, ng/mL, p <
0.0001). In contrast, the leptin levels in the PF were not
different (control = 6.68 ± 0.43, endometriosis = 7.71 ±
0.59, ng/mL, p = 0.18) (Fig. 1a). However, comparing
the women with and without ovarian implant, both the
serum (with ovarian implant = 15.85 ± 1.99; without
ovarian implant = 23.14 ± 2.60; ng/mL, p = 0.04) and PF
(with ovarian implant = 4.28 ± 1.30; without ovarian im-
plant = 11.18 ± 2.98;ng/mL, p = 0.05) leptin levels were
significantly higher in the women who did not have an
ovarian implant (Fig. 1b).
The leptin levels in the serum and PF of patients in the
peritoneal endometriosis group are presented in Fig. 2.
The leptin levels in the PF were significantly lower than
those in the serum (serum= 19.25 ± 1.84; PF = 7.72 ± 1.78;
ng/mL, p = 0.0004). Figure 3 shows there is no difference
in the estradiol serum levels between the endometriosis
and control groups (control = 45.17 ± 14.11; endometri-
osis = 47.83 ± 18.92; pg/mL, p = 0.9192). However, in the
control group, the PF estradiol levels were lower than in
the endometriosis group (control = 14.30 ± 1.71; endomet-
riosis = 21.15 ± 1.56; pg/mL, p = 0.0168).
Protein expression
The protein expression of aromatase shows that the im-
plants found in the vaginal septum have the highest ex-
pression level, while the intestine implants have the low
levels of this enzyme. The implants found in the uterosa-
cral ligaments had intermediate values (Fig. 4). Addition-
ally, this expression does not seem to correlate with the
estradiol levels in the PF (Fig. 5). The protein expression
of leptin and its receptor, ObR, had the same pattern of
Table 1 Baseline characteristics of the patients and the ectopic implant numbers
Age BMI (kg/m2) Ectopic implant numbers
Control group (n = 10) 33.10 ± 2.32 24.37 ± 0.81 -
Endometriosis group (n = 15) 32.87 ± 1.16 22.51 ± 1.60 2.6 ± 0.33
Values are given as the mean ± standard error of the mean (SEM). The number in parentheses corresponds to the number of samples. There was no significant
difference between the two groups
Fig. 1 The serum and peritoneal fluid leptin levels in control (white
bar) and peritoneal endometriosis (black bar) women (a). The serum
and peritoneal fluid leptin levels in peritoneal endometriosis patients
with and without ovarian implants (b). Values are given as the
mean ± standard error of the mean (SEM). The number in
parentheses corresponds to the number of samples
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higher expression in the vaginal septum lesions and lower
expression in the intestine lesions (Fig. 6).
Discussion
Leptin, a hormone that is mainly produced by adipo-
cytes [6], is also expressed in endometrium and has
been implicated in endometriosis [26]. The interest in
the understanding of the association between leptin
and endometriosis has been increasing. An interesting
finding about leptin and endometriosis is that patients
with peritoneal implants at all stages of endometriosis
show higher PF leptin concentrations than women in
whom no implant was observed, suggesting that lep-
tin may play a role in the development of peritoneal
endometriosis [14].
However, the studies found in the literature on this topic
are controversial, which could be related with the variability
in the control groups. Women usually included in this
group undergo surgery for infertility without a known cause
[5, 14, 21] or tubal ligation [5, 13, 14, 20], miomas [20], or
other pathologies that are different from endometriosis [13,
14, 26]. In an attempt to reduce the bias of this control, the
endometriosis group in this study consisted of women with
stage IV endometriosis. For the control group, we recruited
subjects from among women who were already scheduled
to undergo surgery for tubal ligation. In this line of think-
ing, all women of both groups were under hormonal ther-
apy, reducing the hormonal variations and influences of
the menstrual cycle, which was confirmed by the simi-
lar estradiol serum values between the groups. Another
inclusion criterion was BMI. Only women with BMI
values between 20.4 to 25.4 kg/m2 were included in this
study because endometriosis is inversely associated
with BMI [27, 28].
Studies evaluating the serum and peritoneal fluid levels
of leptin in patients with endometriosis report conflict-
ing results of both high levels [5, 13–18] or unchanged
levels [15, 19–22]. No studies in the literature have eval-
uated stage IV patients alone. Again, we believe that the
variability among the studies in relation to patient cri-
teria is responsible for the discrepancy in the results. In
addition to the criteria already discussed for the bias in
the control group, the studies reported great variability
in the endometriosis group in relation to BMI, use or
not of hormonal therapy and stage of disease. All of
these variables are responsible for the controversy in the
Fig. 2 The leptin levels in the serum and peritoneal fluid of
patients in the peritoneal endometriosis group. Values are given
as the mean ± standard error of the mean (SEM). The number in
parentheses corresponds to the number of samples
Fig. 3 The serum and peritoneal fluid estradiol levels in control
(white bar) and peritoneal endometriosis (black bar) groups. Values
are given as the mean ± standard error of the mean (SEM). The
number in parentheses corresponds to the number of samples
Fig. 4 Twenty micrograms of protein were resolved on SDSPAGE,
which was followed by immunoblot analysis with specific antibodies
against aromatase in intestine lesions (INT), uterosacral ligament
lesions (UL) and vaginal septum lesions (VS) in peritoneal
endometriosis patients. Representative bands of results are provided
above the graphs. Β-actin was used as an internal control. Values are
given as the mean ± standard error of the mean (SEM). The number
in parentheses corresponds to the number of samples
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literature, which makes the role of leptin in the path-
ology of endometriosis an enigma.
Recently we have published a study on endometriosis
stage IV patients [29] in which we found that that leptin
levels in both the serum and PF were changed. In
addition, in the cystic fluid of endometrioma, the leptin
levels were very high compared to the serum and PF. In
this study, we showed that endometriosis patients pre-
sented with high levels of serum leptin, while the peri-
toneal fluid levels were unchanged compared to the
control ones. We could attribute the difference in the
leptin serum levels to the high number of patients en-
rolled in the present study.
Analyzing leptin in women with peritoneal endometri-
osis with and without ovarian implants, we found that in
peritoneal endometriosis without ovarian implants, the
leptin serum and peritoneal fluid levels were higher than
in women with ovary implants. Together with data from
literature [13], these data suggest that the presence of
peritoneal disease, and not of an ovarian implant, is the
Fig. 5 Pearson’s correlation between the protein aromatase
expression and peritoneal fluid estradiol levels in the vaginal septum
(a), intestine (b) and uterosacral ligament (c)
Fig. 6 Twenty micrograms of protein were resolved on SDSPAGE,
which was followed by immunoblot analysis with specific antibodies
against leptin (a) and ObR (b) in intestine lesions (INT), uterosacral
ligament lesions (UL) and vaginal septum lesions (VS) in peritoneal
endometriosis patients. Representative bands of the results are
shown above the graphs. β actin was used as an internal control.
Values are given as the mean ± standard error of the mean (SEM).
The number in parentheses corresponds to the number of samples
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factor that influences the concentration of leptin in the
serum and PF in endometriosis. This result and the fact
that the cystic fluid of endometrioma has high levels of
leptin compared to serum and PF [29] suggest that the
leptin produced by the ovary implant could be seques-
tered to the endometrial cyst instead of going to the
serum or peritoneal fluid.
The leptin regulation by steroid is another controversial
point. Data from animal models suggest that gonadal ste-
roids modulate leptin expression [30–32]. The leptin con-
centrations are higher among women than among men,
which is explained by the positive regulation of estrogen
on leptin secretion, while androgen negatively regulates
these levels [33–36]. In addition, the increased fat depots
in women could also explain this gender difference [37].
The leptin levels in premenopausal women are higher
than those in postmenopausal women [38]. Additionally,
it is known that leptin can either vary during the men-
strual cycle, higher at the luteal phase [31, 39] or not, even
in women under hormonal therapy [5, 40, 41]. The endo-
metriosis group showed no difference in the estradiol
serum levels, while the peritoneal fluid is lower than in
the control group. Based on these results and the fact that
estrogen positively regulates leptin, the endometriosis
group should have normal serum and low PF leptin levels.
Therefore, we could assume that this regulation is missed
in these endometriosis patients. More studies are in devel-
opment in our lab to establish a possible relationship be-
tween leptin expression and the number or site of focus.
It is known that ectopic endometriotic tissues have
estrogen-producing ability [31, 42, 43]. In attempt to
correlate the estradiol production by each ectopic im-
plant with the peritoneal fluid estradiol level, the aroma-
tase expression was evaluated. Although there was a
non-significant correlation between peritoneal fluid es-
tradiol and a local ectopic implant aromatase expression
(most likely by the small number of samples), the results
suggest a positive correlation in the vaginal septum im-
plant and a negative correlation in the intestine implant.
However, in spite of the fact that aromatase enzyme
seems to be expressed differently in each ectopic endo-
metriotic implant, it is not sufficient to explain why its
expression is lower compared to the control women.
Further analysis is necessary to evaluate whether the
healthy tissue that surrounds the implant can have a
regulatory role on disease progression.
In relation to the leptin expression, the results were
very similar with those for aromatase. Both leptin and its
receptor, ObR, were higher in the vaginal septum im-
plant compared to the intestine implant. The implant
found in the uterosacral ligament expresses medium
values of both proteins. A recent paper reported that the
peritoneal implants express high leptin and ObR than
eutopic endometrium [44]. We did not find any paper
that compared the expression of aromatase, leptin or
ObR among the different peritoneal ectopic implants;
however, because leptin has angiogenic and immuno-
logic proprieties [45, 46], the high expression of both
leptin and its receptor could be related to the migration
of the endometrium to its implant site.
Conclusion
This study reports some interesting associations between
the leptin levels in the serum, peritoneal fluid, tissue sam-
ples and the localization of the ectopic endometrium. Al-
though this study does not give a clear picture of the role
of leptin in the development and progression of peritoneal
implants, it contributes new data that might be useful to
elucidating the enigma that is the role of leptin in endo-
metriosis disease.
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